BRIEF-Kadmon Receives FDA Guidance On Pivotal Clinical Trial Design For KD025 In Chronic Graft-Versus Host Disease
April 10, 2018 at 08:01 AM EDT
* ARM, PIVOTAL PHASE 2 CLINICAL TRIAL TO SUPPORT POTENTIAL REGISTRATION OF KD025 IN CGVHD Source text for Eikon: Further company coverage:
